Literature DB >> 11383377

New therapies on the horizon.

W V Brown.   

Abstract

Statins have proved to be potent drugs for reducing low-density lipoprotein cholesterol (LDL-C) levels. However, because the response to current statin therapy regimens is not always sufficient to reach defined goal levels, additional drugs to lower LDL-C are needed. New drugs may soon be available to lower LDL-C levels by mechanisms that differ from those of the statins. Among these new agents are a bile acid binding resin, inhibitors of bile acid transport, inhibitors of cholesterol transport, inhibitors of cholesterol esterification, and triglyceride-lowering agents.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11383377

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  2 in total

1.  Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.

Authors:  Michael R Jones; Brian A Baker; Philip Mathew
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Current Perspectives on rosuvastatin.

Authors:  Miao Hu; Brian Tomlinson
Journal:  Integr Blood Press Control       Date:  2013-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.